162 related articles for article (PubMed ID: 35169095)
1. [Current Topics on Precision Medicine for Neurofibromatosis Type 2].
Hiruta R; Fujii M
No Shinkei Geka; 2022 Jan; 50(1):150-161. PubMed ID: 35169095
[TBL] [Abstract][Full Text] [Related]
2. Diagnosis, Management, and New Therapeutic Options in Childhood Neurofibromatosis Type 2 and Related Forms.
Ruggieri M; Praticò AD; Evans DG
Semin Pediatr Neurol; 2015 Dec; 22(4):240-58. PubMed ID: 26706012
[TBL] [Abstract][Full Text] [Related]
3. Childhood neurofibromatosis type 2 (NF2) and related disorders: from bench to bedside and biologically targeted therapies.
Ruggieri M; Praticò AD; Serra A; Maiolino L; Cocuzza S; Di Mauro P; Licciardello L; Milone P; Privitera G; Belfiore G; Di Pietro M; Di Raimondo F; Romano A; Chiarenza A; Muglia M; Polizzi A; Evans DG
Acta Otorhinolaryngol Ital; 2016 Oct; 36(5):345-367. PubMed ID: 27958595
[TBL] [Abstract][Full Text] [Related]
4. Current progress in genomics and targeted therapies for neurofibromatosis type 2.
Hiruta R; Saito K; Bakhit M; Fujii M
Fukushima J Med Sci; 2023 Aug; 69(2):95-103. PubMed ID: 37468280
[TBL] [Abstract][Full Text] [Related]
5. [Neurofibromatosis type 2 (central neurofibromatosis or bilateral acoustic neuromas, vestibular schwannomas): from phenotype to gene].
Sabol Z; Kipke-Sabol L; Miklić P; Hajnsek-Propadalo S; Sabol F
Lijec Vjesn; 2006; 128(9-10):309-16. PubMed ID: 17128670
[TBL] [Abstract][Full Text] [Related]
6. Advances in Targeted Therapy for Neurofibromatosis Type 2 (NF2)-Associated Vestibular Schwannomas.
Cumpston EC; Rhodes SD; Yates CW
Curr Oncol Rep; 2023 May; 25(5):531-537. PubMed ID: 36933171
[TBL] [Abstract][Full Text] [Related]
7. Neurofibromatosis Type 2 (NF2) and the Implications for Vestibular Schwannoma and Meningioma Pathogenesis.
Bachir S; Shah S; Shapiro S; Koehler A; Mahammedi A; Samy RN; Zuccarello M; Schorry E; Sengupta S
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33445724
[TBL] [Abstract][Full Text] [Related]
8. Sustained response to bevacizumab in a patient with mosaic neurofibromatosis type 2 carrying the
Basenach E; Förster A; Raab P; Alzein S; Schmidt G; Krauss JK; Schlegelberger B; Heidenreich F; Auber B; Hartmann C; Wiese B; Weber RG
Clin Neuropathol; 2022; 41(4):162-167. PubMed ID: 35445657
[TBL] [Abstract][Full Text] [Related]
9. New classification and approaches to the treatment of schwannomatosis.
Makashova ES; Zolotova SV; Absalyamova OV; Galkin MV; Petrokovskaya AV; Kozlov AV; Golanov AV
Zh Vopr Neirokhir Im N N Burdenko; 2023; 87(5):104-109. PubMed ID: 37830475
[TBL] [Abstract][Full Text] [Related]
10. Neurofibromatosis type 2.
Evans DG; Sainio M; Baser ME
J Med Genet; 2000 Dec; 37(12):897-904. PubMed ID: 11106352
[TBL] [Abstract][Full Text] [Related]
11. Frequent NF2 gene transcript mutations in sporadic meningiomas and vestibular schwannomas.
Lekanne Deprez RH; Bianchi AB; Groen NA; Seizinger BR; Hagemeijer A; van Drunen E; Bootsma D; Koper JW; Avezaat CJ; Kley N
Am J Hum Genet; 1994 Jun; 54(6):1022-9. PubMed ID: 7911002
[TBL] [Abstract][Full Text] [Related]
12. [Molecular Biological Background of Neurofibromatosis Type 2].
Miyawaki S; Teranishi Y; Saito N
No Shinkei Geka; 2022 May; 50(3):572-577. PubMed ID: 35670170
[TBL] [Abstract][Full Text] [Related]
13. Neurofibromatosis type 2 (NF2): diagnosis and management.
Lloyd SK; Evans DG
Handb Clin Neurol; 2013; 115():957-67. PubMed ID: 23931824
[TBL] [Abstract][Full Text] [Related]
14. Targeted deep sequencing of DNA from multiple tissue types improves the diagnostic rate and reveals a highly diverse phenotype of mosaic neurofibromatosis type 2.
Teranishi Y; Miyawaki S; Hongo H; Dofuku S; Okano A; Takayanagi S; Ota T; Yoshimura J; Qu W; Mitsui J; Nakatomi H; Morishita S; Tsuji S; Saito N
J Med Genet; 2021 Oct; 58(10):701-711. PubMed ID: 33067351
[TBL] [Abstract][Full Text] [Related]
15. Neurofibromatosis type 2.
Slattery WH
Otolaryngol Clin North Am; 2015 Jun; 48(3):443-60. PubMed ID: 26043141
[TBL] [Abstract][Full Text] [Related]
16. Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2.
Blakeley JO; Evans DG; Adler J; Brackmann D; Chen R; Ferner RE; Hanemann CO; Harris G; Huson SM; Jacob A; Kalamarides M; Karajannis MA; Korf BR; Mautner VF; McClatchey AI; Miao H; Plotkin SR; Slattery W; Stemmer-Rachamimov AO; Welling DB; Wen PY; Widemann B; Hunter-Schaedle K; Giovannini M
Am J Med Genet A; 2012 Jan; 158A(1):24-41. PubMed ID: 22140088
[TBL] [Abstract][Full Text] [Related]
17. Neuropathology and molecular genetics of neurofibromatosis 2 and related tumors.
Louis DN; Ramesh V; Gusella JF
Brain Pathol; 1995 Apr; 5(2):163-72. PubMed ID: 7670657
[TBL] [Abstract][Full Text] [Related]
18. Neurofibromatosis type 2.
Evans DG
Handb Clin Neurol; 2015; 132():87-96. PubMed ID: 26564072
[TBL] [Abstract][Full Text] [Related]
19. Neurofibromatosis type 2 attributable to gonosomal mosaicism in a clinically normal mother, and identification of seven novel mutations in the NF2 gene.
Sestini R; Vivarelli R; Balestri P; Ammannati F; Montali E; Papi L
Hum Genet; 2000 Oct; 107(4):366-71. PubMed ID: 11129337
[TBL] [Abstract][Full Text] [Related]
20. Neurofibromatosis type 2 in the elderly population: clinical and molecular features.
Goutagny S; Bah AB; Parfait B; Sterkers O; Kalamarides M
Am J Med Genet A; 2013 Apr; 161A(4):667-70. PubMed ID: 23322716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
